Nivolumab Treatment for the Patients with Gastric Cancer-Present and Future
Imazeki, H.; Kato, K.; Boku, N.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(10): 1513-1523
2019
ISSN/ISBN: 0385-0684 PMID: 31631132 Document Number: 699062
Nivolumab, anti-PD-1 monoclonal antibody, has innovated treatment ofpatients with gastric cancer. Nivolmab has been indicated forBthird-line treatment ofgastric cancer patients in September 2017. Although it has been more than 1 year after nivolumab being widely used in practice, we still have many clinical questions in this population. We leverage evidence obtained from other types of cancer where we have more experience to use nivolumab to answer these questions step by step, but it is still far from enough with some complexities unique to gastric cancer. While nivolumab monotherapy has shown long term survival in some patients, more than halfofpatients experience disease progression right after treatment initiation with nivolumab. Because we have other treatment options, it is urgent to identify biomarkers to predict its efficacy. Now clinical trials ofimmune -checkpoint inhibitors in various treatment line are ongoing with translational research including biomarker analysis and we highly expect those outcome.